Jose Carlos Segovia
Head of the Cellular Technology Division at CIEMAT, Madrid, Spain. Focused his career in hematopoietic stem cells (HSC), and in lentiviral gene therapy and gene editing strategies for hematopoietic and liver inherited diseases. He has published more than 100 scientific articles, has obtained 10 patents, two of them already licensed, and got 5 orphan drug designations by EMA and FDA. A first-in-human clinical trial for the treatment of Pyruvate Kinase Deficiency, sponsored by Rocket Pharma, with very good preliminary results is ongoing thanks to his preclinical development.